 REHOVOT, Israel, March 31, 2021 GLOBE NEWSWIRE -- Kamada Ltd. NASDAQ TASE: KMDA, a plasma-derived biopharmaceutical company, today announced top-line results from its Phase 12 open-label, single-arm, multi-center clinical trial in Israel of the Companys anti-SARS-CoV-2 plasma-derived hyperimmune globulin IgG treatment for coronavirus disease COVID-19. Interim results from this study were announced by Kamada in September 2020. 